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Abortive attempts at DNA repair can contribute to the 
effects of DNA damage inflicted by cytotoxic drugs. 
DNA methylation damage, 64hioguanine and cisplatin 
adducts all owe their cytotoxicity in part to the 
intervention of DNA mismatch repair. 
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DNA repair is a good thing. It is there to help the cell 
reverse the damage done to its DNA by a hostile environ- 
ment and ensure faithful duplication of the genome in each 
generation. DNA repair prevents the accumulation of muta- 
tions that might lead to cellular dysfunction or cell death. 
There are numerous examples of inherited syndromes in 
which defective repair is accompanied by increased rates 
of mutation and sensitivity to killing by DNA damaging 
agents as diverse as ultraviolet light and water [I]. A major 
DNA-repair pathway is mismatch correction, whose princi- 
pal function is to scan newly synthesized DNA and remove 
errors committed by the DNA polymerases 121. Mismatch 
repair has been the focus of a considerable amount of recent 
attention because of its association with human cancer. In 
the hereditary nonpoiyposis colorccta! cancer syndrome, an 
inherited mutation in one of four known mismatch-repair 
genes is associated with extremely high rates of early onset 
colorectal and other malignancies [3]. The message is 
clear - the mismatch-repair system serves an important 
function in preventing the cell from becoming malignant. 
Mismatch repair may not always be so benevolent, 
however, and a number of recent papers have highlighted 
the contribution that this important DNA-repair pathway 
can sometimes make to cell death. 
DNA methylation damage 
A recent paper 141 suggests that cell death in response 
to 06-methylguanine (O”-meGua) and 6thioguanine may 
occur via a common pathway that involves abortive DNA 
repair, and that S-adenosyimethionine (SAM) may be’ 
important in generating the correct substrate from 
6-thioguanine for this pathway. Methylating agents kill 
c&s, and the formation of 06-meGua in DNA is an 
important part of this cycotoxicity IS]. The apparently 
ubiquitous distribution of a specific DNA repair enzyme, 
06-methylguaninc-DNA methylcransferase (MGMT), 
which selectively catalyzes the reversion of the modified 
base to guanine, implies the existence of a prevalent 
source of ‘endogenous’ DNA methylation damage. SAM, 
one of the molecules that shuttle methyl groups around 
the cell for use in biosynthetic reactions, was identified as 
a candidate DNA methylacing agent that can methylate 
DNA by a non-enzymatic methyl group transfer [6]. It 
was realized, however, that this compound was unlikely to 
generate a significant amount of 06-meGua, because the 
reaction mechanism by which SAM transfers its methyl 
group to DNA dictates that donation to an oxygen will 
occur only slowly. Peter Swann reasoned that a sensitive 
indicator of possible OG-methylation might be generated 
by replacing the 06-atom with sulphur, to which methyl- 
group transfer should be easier. Thus, armed with syn- 
thetic oligonucleocides containing &thioguanine, he and 
his colleagues demonstrated [4] that the rate of mechyl- 
group transfer to the Y$osition is several 1000-fold 
higher than to the 06-position. Of course, this still leaves 
SAM as a poor methylator of guanine oxygen atoms, but, 
in an important insight, Swann and his colleagues realized 
that the facife methylation of h-thioguanine might under- 
lie the cytotoxicity of an important class of antitumor 
chemotherapeutic drugs. 
Mercaptopurine and 64hioguanine 
Mercaptapurine and 6chioguanine are used in the treat- 
ment of acute leukaemia. These agents are incorporated 
into DNA after being metabolized by the pathway that 
recycles purine bases. Methylation-tolerant cell lines, 
which have acquired a resistance to the presence of poten- 
tially cytotoxic 06-meGua in their DNA through defects in 
DNA mismatch repair [7], generally exhibit a cross-resis- 
tance to &thioguanine, despite having a functional pusine 
recycling pathway. Tolerant cells incorporate 6-thioguanine 
into DNA as do the normal cells, but only the former can 
continue to replicate the DNA that contains 6-chioguanine 
without detrimental effects [S]. 
Precisely how defects in mismatch repair confer methyla- 
tion tolerance is not known, but Swann etaE. [4] modified 
a currenr model co explain how Cthioguanine, with the 
help of mismatch repair, might kill normal cells and how 
death is avoided in mismatch-repair-defective cells. They 
propose the following sequence of events: the base analog 
is incorporated into DNA where it serves as an acceptor 
for facile chemical methyiation by intracellular SAM. 
During the next round of DNA replication, the resulting 
S6-meThioguaninc base pairs with thymine about half of 
the time. S6-meThioguaninc*T base pairs arc recognized 
by the mismatch-repair sysccm which mistakenly identi- 
fies them as bona&% replication errors. Engagement of 
mismatch correction at 5%meThioguanine*T base pairs 
kills the cell in the same way that aberrant processing of 
06-me&a-containing base pairs by this pathway results 
in cell death. Death is thought to be a consequence of 
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Figure 1 
Proposed mechanism of 6-thioguanine 
cytotoxicity [4]. 6-thioguanine (6-TG) enters 
the cell and is converted via hypoxanthine- 
guanine phosphoribosyltransferase, 
reductase and kinase activities into deoxy-6- 
thioguanine 5’.triphosphate (dS”GTP). The 
use of dS6GTP by DNA polymerases during 
DNA replication introduces dSEGMP 
(abbreviated to S-TG here) into DNA. 6;TG 
in DNA is subjected to infrequent non- 
enzymatic methylation by cellular 
S-adenosylmethionine (SAM) to farm 
dS%teGMP. During the next round of DNA 
replication, methylated 6-TG may direct the 
incorporation of thymine (T) as the 
complementary base. The imperfect 
S6-meGua*T base pair is recognized by the 
mismatch-binding complex hMutSol which 
initiates an attempt at mismatch repair. 
Attempted repair of the mismatch fails, in 
part, because the removal attempts are 
directed to the newly synthesized daughter 
DNA strand, whereas the ‘incorrect’ 
(Sa-meThioguanine) base remains in the 
parental strand. The persistent 
WmeThioguanine is able to provoke further 
incomplete repair attempts. The long-lived , 
interruptions in the daughter DNA strand 
opposite S6-meThioguanine bases are 
potentiafly cytotoxic intermediates. 
the repair attempts being targeted to the daughter DNA 
strands, which, by definition, normally contain the repli- 
cation errors. In the case of damage-provoked mismatch 
repair, the altered (or ‘incorrect’) base remains unexcised 
in the parental DNA strand. This unexcised methylated 
base will, on completion of the ‘repair’ of the daughter 
strand, provoke another repair attempt. These repeated 
mismatch-repair attempts generate long-lasting jncerrup- 
tions in the daughter DNA strand that eventually lead to 
cell death [7]. Thus, in cells that are mismatch repair 
deficient, neither 06-meGua nor S”-meThioguanine is 
particularly cycocoxic. L 
We have summarized the broad outline of this model in 
Figure 1, Swarm et crl. [4] present compelling experimental 
evidence in support of each of the postulated steps, and 
the suggested sequence of events nicely explains the char- 
acteristic delayed cytotoxicicy and chromosomal damage 
produced by 6-thioguanine. Their model also resolves the 
question of why vastly greater numbers of 6-thioguanine 
bases than 06-meGua bases are present in DNA at similar 
levels of cell killing [8]. From direct analysis of S6- 
meThioguanine in cellular DNA, they estimate that only 
relatively few incorporated 6-thioguanines (estimated at 
about 2 of every 10~000) become methylated, thus gaining 
the potential to pair with thymine and.become cytotoxic. 
Despite similar mechanisms of action, S6-meThioguanine 
and 06-meGua do have demonstrably diffeient effects on 
cells. Perhaps this is not surprising. 6-thioguanine is used 
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as a cytotoxic agent, whereas DNA methylating agents 
are renowned mutagens. The relationship between cyto- 
toxicity and mutagenicity is different for S6-meThiogua- 
nine and @-meGua. @-meGua-induced mutations can 
be observed under conditions of relatively high cell sur- 
vival in both wild-type and mismatch-repair-defective 
cells, In contrast, 6-thioguanine (and by implication S6- 
meThioguanine) is detectably mutagenic only in repair- 
defective cells because it is too toxic towards wild-type 
cells [9J. In other words, S6-meThioguanine is very cyto- 
toxic but not very mutagenic, whereas the converse is 
true for Cl”-meGua. 
What is the reason for these differences? Replication 
of U6-meGua- results in a large preponderance of 06- 
meGua+T base pairs over 06-meGua*C pairs. in contrast, 
the replication products of %meThioguanine seem 
likely to be equally divided between S6-meThiogua- 
nine*C and S6-meThioguanine~T base pairs. The 
hMutSol mismatch-recognition complex binds more favor- 
ably to S6-meThioguaninemT and to 06-meGua.T than 
to the corresponding C-containing base pairs. Because 
S6-meThi0guanine.C is a more frequent replication 
product than 06-meGua*C, this suggests, somewhat para- 
doxically, that S6-meThioguanine might not provoke as 
many potentially cytotoxic repair attempts as O”-meGua. 
The equation is not this simple, however; the recently 
identified hMut@ mismatch-recognition complex [lo] 
might initiate correction attempts at these C-containing 
base pairs, and it is known that 06-meGua*C base pairs 
can provoke mismatch-repair attempts [ll]. A more 
straightforward explanation for the differences in cytotox- 
icity and mutagenicity between S6-meThioguanine and 
04-meGua might lie in the relative affinity of the hMutSa 
complex for for the different methylated bases paired to 
T If recognition by hMutSu of S6-meThioguanine*T 
base pairs is more favorable than that of 06-meGua.T 
pairs, cells are more likely to mount death-prone repair 
attempts on the former and to allow the persistence of the 
promutagenic 06-meGua*‘f base pairs. 
Azathioprine, a drug that is related to mercaptopurine and 
&thioguanine, has been widely used as an immunosup- 
pressant in renal transplant patients. Azathioprine is 
metabolised to 6-thioguanine, which is incorporated into, 
DNA. Swann and his collaborators [4] suggest that incor- 
poration of 6-thioguanine and its subsequent methylation 
might contribute to the development of the cancers that 
are inevitably associated with organ transplants. They 
propose that S6-meThioguanine may either act directly as 
a mutagen or facilitate the selection of mismatch-repair- 
defective cells. There is some experimental support for 
these possibilities in an animal system. 6-chioguanine 
can induce ‘xenogenization’, a process by which tumor 
cells become non-rumorigenic in syngeneic hosts [12]. 
The effect relies on the generation of mutated cellular 
proteins as sources of new antigens, which elicit cytocoxic 
T-cell responses. Methylacing agents, either acting as 
direct mutagens or as selective agents for a mucator phe- 
notype, are good inducers of xenogenization [13]. Treat- 
ment in w&--o with 6thioguanine can thus apparently lead 
to the production of mutaced proteins. In transplant 
patients, this could result in neoplastic transformation. 
Overall, however, it seems likely that the increased inci- 
dence of tumors is mainly a consequence of immune sup- 
pression per se. After all, tumors arise in recipients of 
immunosuppressive regimes that are not known to induce 
mutations, and in many cases the tumors appear to have a 
viral aetiology. In addition, as pointed out above, 
6thioguanine is a rather poor mutagen. Nonetheless, it 
would seem prudent to explore this potential mechanism 
of tumorigenesis further. 
Cisplatin 
The possibility that mismatch repair might be involved 
in the lethality of another important ancitumor agknt, 
cisplatin, was raised some time ago [14]. Recently it has 
been established that ovarian carcinoma cells selected b 
witpo for resistance to this agent have defects in mismatch 
repair, as do cells tolerant to methylating agents and 
6-thioguanine [15-171. Cisplatin is one of the success 
stories of chemotherapy. It is a highly effective treatment 
of testicular and ovarian tumors although, as with all anti- 
tumor therapies, resistance develops. Considerable effort 
is being expended to investigate the interaction of human 
mismatch-repair factors with cisplarin-modified DNA. 
The first results from Derek Duckett and coworkers in the 
laboratory of Paul Modrich [18] and Jill Mello in John 
Essigmann’s laboratory in collaboration with Samir 
Acharya and Richard Fishel [19], indicate that human 
mismatch recognition proteins can interact with DNA 
containing cisplatin-1,2-diguanyl inrrastrand crosslinks. 
These are the -major DNA adducts of cisplatin and proba- 
bly contribute most to its cytotoxic effect. Ducketc et al. 
[18], using a subscrate that contained a single 1,Zdiguanyl 
intrastrand cisplatin crosslink, demonstrated that the mod- 
ified DNA was recognized by an extensively purified 
mismatch recognition factor, hMucSol. hMutSa is a het- 
erodimer composed of hMSH2 and hMSH6/GTBP (G/T 
binding protein) subunits [ZO,Zl] (see Fig. l), and it initi- 
ates mismatch repair by binding to mismatched DNA. 
Both subunits are homologues of an E. coli mismatch- 
recognition protein (MutS), and recognition of cisplatin 
damage could conceivably be initiated by either of them. 
Mello etul. [19] report that cisplatin-damaged DNA can be 
recognized by the purified hMSH2 subunit acting alone. 
These biochemical studies use large excesses of binding 
factor over cisplatin-modified DNA, so it is not clear what 
happens in a cisplatin-treated cell and whether hMSH2 or 
hMutSrY carries out the recognition of cisplatin-modified 
DNA. Nevertheless, the findings establish the important 
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principle that mismatch-recognition factors are IikeIy to 
initiate mismatch-repair attempts at cisplatin adduccs. In 
an intriguing addendum to their binding data, Mello 
ef & demonstrate that hMSHZ expression is apparently 
highest in testis and ovary, the two tissues in which tumors 
are most responsive to cisplatin therapy. If hMSH2 levels 
reflect the cell’s capacity to initiate mismatch-repair 
attempts at cisplatin adducts, and by implication cell 
death, these data strongly support the idea that cisplatin is 
another addition to the list of drugs that kill cells by pro- 
voking mismatch repair to misbehave. 
Mismatch repair and other drugs 
The contribution of the mismatch-repair pathway to the 
cytoroxicity of Ob-meGua and 6-thioguanine (now 
S6-meThioguanine) was consistent with their similarity to 
unmodified guanine and their abilities to participate in 
some kind of aberrant base pairing. The inclusion of cis- 
platin crosslinks into the list seems to have removed the 
requirement of StrUCtUEd similarity co unmodified guaninc 
for recognition by the mismatch-repair pathway (although 
the potential effects of these adducts on base-pairing 
during DNA replication are not yet fully known). Indeed, 
resistance to the therapeutic agent doxorubicin can also be 
acquired by loss of mismatch repair [l&17]. This drug may 
be cytotoxic rhrough its ability to intercalate between the 
two DNA strands, or it may generate DNA-base-damaging 
oxygen radicals. 
What is required for recognition by the mismatch-repair 
machinery? One property shared by 06-meGua and 1,2- 
diguanyl crosslinks generated by cisplatin is their relative 
ease of replication. O%eGua is not a good replication 
block and is copied quite well by DNA polymerases. Until 
recently, 1,Zdiguanyl crosslinks seemed refractory to 
bypass by purified DNA polymerases, but it now appears 
that these fesions might be bypassed more frequently than 
previously supposed [Z?]. As mismatch repair is a post- 
replicative process, it is perhaps more likely to be pro- 
voked by drug-damaged DNA that has undergone 
replication. In this case, candidates for lethal processing by 
mismatch repair might be identified by a relative inability 
to arrest DNA replication. A second, not exclusive, possi- 
bility is that mismatch repair becomes involved when the 
normal excision (or reversal) of DNA damage is inade- 
quate. The mismatch-repair-related cytotoxic effects of 
06-meGua are most obvious in Mex- cells, which express 
very low levels of MGM’C this enzyme can be considered 
the first line of defence against these methylated bases [S]. 
Cisplarin may be cytotoxic towards wild-type cells ac least 
partly because the 1,2-diguanyf crosslinks are poor sub- 
strates for nucleotide excision repair [23]. 
Perhaps we should look for a contribution by.mismatch 
repair to the cytotoxicity of any drugs that introduce DNA 
lesions that are not particularly good substrates for the 
normal protective DNA repair pathways of nucleotide and 
base excision repair. Might the interaction of mismatch 
repair proteins wirh drug-damaged DNA generally have a 
beneficial outcome after all? Mismatch repair would serve 
a positive and advantageous function for. the tissue (or 
organism) if it deleted cells that have incurred too much 
DNA damage. 
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